News

Find updates on the work of our researchers here, as well as news about recent advances in Alzheimer's science, funding and awareness.

An “Inside-Out View” of Alzheimer’s: Study Offers New Take on Amyloid Hypothesis

A new "alternative amyloid hypothesis” from the lab of Dr. Charles Glabe, at the University of California at Irvine, helps explain precisely how neurons (nerve cells) die in Alzheimer’s disease and how known genetic mutations initiate a chain reaction in this long process. The important new hypothesis was driven by research supported by Cure Alzheimer’s Fund, and has just been being published in the Journal Neurobiology of Disease. Dr.

Are Brain Cell Regeneration Drugs Ready for Prime Time?

A promising first-in-class drug stimulates the creation of new nerve cells in the brains of Alzheimer's mice and will soon be tested in the brains of human patients, thanks to new research by Dr. Sam Gandy, member of Cure Alzheimer's Fund's Research Consortium, at Mount Sinai School of Medicine in New York.

16 Cure Alzheimer’s Fund Scientists Listed Among World’s Most Influential

A prestigious new list of the "World's Most Influential Scientific Minds" includes 16 scientists closely associated with Cure Alzheimer's Fund.

Interview with William Mobley, M.D., Ph.D.

Born in landlocked Nebraska, William Mobley discovered the wonders of research when he first studied a sea cucumber’s hemoglobin. Now a prominent academic neurologist and the newest member of Cure Alzheimer’s Fund’s Scientific Advisory Board, Mobley’s passion for science and for living life never has waned.

Alzheimer’s and Down Syndrome: Overlap and Opportunity

The world already is very familiar with both Alzheimer’s disease (AD), primarily a disease that occurs in the elderly, and Down syndrome (DS), a genetic condition present at birth. What many don’t realize is that these two conditions also overlap. By age 40, nearly all people born with Down syndrome have begun accruing the plaque and tangle hallmarks of Alzheimer’s. By age 60, most exhibit signs of dementia.

Senate Subcommittee Allocates Additional $100 Million for Alzheimer's Research

On Tuesday, June 10, the Senate Appropriations Subcommittee on Labor, Health & Human Services (LHHS) earmarked an additional $100 million for Alzheimer's research in their 2015 fiscal year funding bill.

How to Erase a Memory – And Restore It

Researchers at the University of California, San Diego School of Medicine have erased and reactivated memories in rats, profoundly altering the animals’ reaction to past events.

The study, published in the June 1 advanced online issue of the journal Nature, is the first to show the ability to selectively remove a memory and predictably reactivate it by stimulating nerves in the brain at frequencies that are known to weaken and strengthen the connections between nerve cells, called synapses.

Alzheimer's and Antidepressants: Dr. Rudy Tanzi Comments

Segment on Alzheimer's disease begins at 3:10.

Last week, many news stories broke about a recent study suggesting levels of amyloid, the sticky substance that builds up in the brain of Alzheimer's patients, may be lowered by the antidepressant Celexa. Dr. Rudy Tanzi, of Harvard Medical School/Massachusetts General Hospital and chair of Cure Alzheimer's Fund's Research Consortium, appeared on the CBS Morning Show to discuss the story.

Promising Update on Efficacy and Safety of “Molecular Tweezers”

Five new publications by Gal Bitan, Ph.D., and colleagues of the David Geffen School of Medicine at UCLA have been released on developing the "molecular tweezer"* CLR01 as a therapeutic drug for Alzheimer's disease and other amyloidoses (conditions involving the build-up of insoluble amyloid proteins).

Diagnosing Alzheimer’s: New Blood Test Suggests Possible Breakthrough

A new blood test, which has the potential to accurately diagnose Alzheimer’s disease in individuals and significantly advance drug testing and research on the disease, has been developed through grant funding by Cure Alzheimer's Fund. 

The test, known as Immunosignature (IS) and developed by a team led by UCLA neurologist Lucas Restrepo, uses a special method of fluorescent tagging of antibodies in the blood to recognize an identifiable binding pattern—or antibody "signature"—associated with Alzheimer's.